UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/650/0.1/18.06.25 | Real-time BOERSE MUENCHEN 11:11:42 03/06/2024 pm IST | ||
| 1.25 EUR | +12.61% |
|
| 1 month | +200.00% | ||
| 3 months | -13.28% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 1.25 | +12.61% |
| 31/24/31 | 1.11 | +20.65% |
| 30/24/30 | 0.92 | -4.17% |
| 29/24/29 | 0.96 | 0.00% |
| 28/24/28 | 0.96 | -15.79% |
Real-time BOERSE MUENCHEN
Last update June 03, 2024 at 11:11 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD1R1A |
| ISIN | DE000HD1R1A1 |
| Date issued | 08/01/2024 |
| Strike | 650 $ |
| Maturity | 18/06/2025 (380 Days) |
| Parity | 10 : 1 |
| Emission price | 1.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.93 € |
|---|---|
| Lowest since issue | 0.25 € |
| Spread | 0.03 € |
| Spread % | 2.36% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Warrants
- Warrant
